Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial

Authors

Subhashis Banerjee (ORCID: https://orcid.org/0000-0001-8971-0006)
L. Liu
Weili Pan
Arkendu Chatterjee (ORCID: https://orcid.org/0000-0001-7884-6928)
Ji‐Chen Ho (ORCID: https://orcid.org/0000-0001-9523-4413)
Xian Jiang (ORCID: https://orcid.org/0000-0001-5109-6055)
Renata M Kisa
Linfeng Li (ORCID: https://orcid.org/0000-0002-8736-6464)
Hao Cheng (ORCID: https://orcid.org/0009-0003-8360-3703)
Yan Lü (ORCID: https://orcid.org/0000-0001-7159-879X)
Shuping Guo (ORCID: https://orcid.org/0009-0006-9634-8432)
Jianzhong Zhang
Yangfeng Ding (ORCID: https://orcid.org/0000-0002-0287-2190)
Ping Wang (ORCID: https://orcid.org/0000-0001-9638-742X)

Institutions

Shanxi Medical University (CN)
Peking University (CN)
Sichuan University (CN)
Sir Run Run Shaw Hospital (CN)
West China Hospital of Sichuan University (CN)
Bristol-Myers Squibb (United States) (US)
Kaohsiung Chang Gung Memorial Hospital (TW)
Peking University People's Hospital (CN)
First Hospital of Shanxi Medical University (CN)
The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
Zhejiang Provincial People's Hospital (CN)
Beijing Friendship Hospital (CN)
Jiangsu Province Hospital (CN)
Shanghai Skin Disease Hospital (CN)
Zhejiang University (CN)
Chongqing Medical University (CN)

Publication Details

Journal: British Journal of Dermatology
Published: 2024-10-22
DOI: https://doi.org/10.1093/bjd/ljae406
Citations: 10
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 2.40

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial

Subhashis Banerjee, L. Liu, Weili Pan, Arkendu Chatterjee et al.

Oct 22, 2024

10 citations

British Journal of Dermatology

Psoriasis: Treatment and Pathogenesis

2.40

article

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial

Subhashis Banerjee, L. Liu, Weili Pan, Arkendu Chatterjee, Ji‐Chen Ho, Xian Jiang, Renata M Kisa, Linfeng Li, Hao Cheng, Yan Lü, Shuping Guo, Jianzhong Zhang, Yangfeng Ding, Ping Wang

October 22, 2024article en

10 citations

Abstract

No abstract available for this paper.

British Journal of DermatologyVol. 192(3)

Shanxi Medical University (CN), Peking University (CN), Sichuan University (CN), Sir Run Run Shaw Hospital (CN), West China Hospital of Sichuan University (CN), Bristol-Myers Squibb (United States) (US), Kaohsiung Chang Gung Memorial Hospital (TW), Peking University People's Hospital (CN), First Hospital of Shanxi Medical University (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Zhejiang Provincial People's Hospital (CN), Beijing Friendship Hospital (CN), Jiangsu Province Hospital (CN), Shanghai Skin Disease Hospital (CN), Zhejiang University (CN), Chongqing Medical University (CN)

Good health and well-being

Openalex Percentile: Top 11%

Psoriasis: Treatment and Pathogenesis

2.40

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial — Subhashis Banerjee, L. Liu, et al. · British Journal of Dermatology (2024) | TGRS Research Map | TGRS